DueCap completed an independent investment screening of a Seed-stage longevity platform combining DEXA-based health measurements, personalized protocols, digital coaching, and recurring membership services.
The company reported approximately $5.7 million in annualized revenue, four operating locations, 1,000 active members, and more than 15,000 lifetime scans. It was raising a $2.0 million Seed round to expand into additional cities, add equipment, develop B2B integrations, and support technology, media, intellectual-property, and regulatory initiatives.
The Screening Objective
The investor needed to understand whether the company’s rapid growth, location economics, member retention, health-outcome claims, and expansion plan were supported by sufficient operating and financial evidence.
DueCap reviewed the company presentation, revenue claims, customer funnel, retention metrics, location model, unit economics, acquisition activity, use of funds, and proposed financing.
What DueCap Identified
The company had progressed beyond the concept stage and presented a distinctive physical-to-digital model. A paid health scan served both as an immediate service and as an acquisition channel into higher-value recurring coaching.
However, several central claims required reconciliation. The reported growth rate did not align with the monthly revenue figures visible in the deck, while the annualized revenue figure needed a clear bridge across locations, subscriptions, and the recently acquired digital business.
The review also found that the reported gross margin, customer acquisition economics, member retention, and rapid location payback depended heavily on definitions and cost-allocation policies that were not supplied. The proposed expansion to multiple markets was not supported by a complete site pipeline, opening schedule, cash budget, or location-level sensitivity analysis.
In addition, the company presented health outcomes and a growing longitudinal dataset, but the materials did not establish causal clinical effectiveness, data rights, regulatory positioning, or the controls required to support medical and performance-related claims.
What DueCap Delivered
- Tested the consistency of reported revenue and growth metrics.
- Separated activity, membership, and payment retention claims.
- Reviewed location build costs, payback assumptions, and expansion exposure.
- Identified the financial and operational effects of the recent acquisition.
- Flagged unresolved clinical, regulatory, privacy, and data-governance questions.
- Defined the minimum evidence package needed for the next investment decision.
Screening Outcome
Additional operating, financial, clinical, and transaction evidence was recommended before advancing the investment review.
The screening shifted the investor’s focus from headline growth toward the quality of revenue, fully loaded location economics, member retention, the validity of health-outcome claims, and whether the proposed Seed round was sufficient to finance the stated expansion plan.
This case is based on a completed DueCap engagement. Company identity and selected transaction details have been withheld or generalized to preserve confidentiality. Company claims were not independently verified by DueCap.